ReviewTheranostics2026
Atherosclerosis nanotheranostics: a perspective from macrophages.
Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mortality rate of cardiovascular diseases (CVDs) has ranked number one in the world over the years. Atherosclerosis (AS), a chronic inflammatory disease, is a key pathological factor in the occurrence and development of CVDs, characterized by lipid accumulation and plaque formation in arteries. Macrophages is the critical contributor to the progression of AS, and macrophage-related pathological processes have received considerable attention as an extremely important target for the diagnosis and treatment of AS. Biomaterial-based nanotechnology offers the possibility of selective and efficient delivery of therapeutic agents to atherosclerotic macrophages, shows the potential to improve the understanding of the pathophysiology of AS, contributes to improve the therapeutic outcomes and imaging accuracy, and further minishes the risk of CVDs. This review provides a well-rounded snapshot of the features, functions, and critical roles of macrophages in the development and progression of AS, as well as the recent advances in the application of macrophage-related nanomaterials in the diagnosis and treatment of AS, with specific emphasis on the design and integration of nanomaterials for specific macrophages-manipulating. Finally, the challenges and prospects of macrophage-based nanotechnologies for the prevention and treatment of AS are also discussed in depth, aiming to inspire innovative thinking and facilitate the ever-fast development of nanomedicine for AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.